FR2928270B1 - Formulation methode pour la prevention ou le traitement des metastases osseuses et autres maladies de l'os - Google Patents

Formulation methode pour la prevention ou le traitement des metastases osseuses et autres maladies de l'os

Info

Publication number
FR2928270B1
FR2928270B1 FR0851521A FR0851521A FR2928270B1 FR 2928270 B1 FR2928270 B1 FR 2928270B1 FR 0851521 A FR0851521 A FR 0851521A FR 0851521 A FR0851521 A FR 0851521A FR 2928270 B1 FR2928270 B1 FR 2928270B1
Authority
FR
France
Prior art keywords
bone
treatment
prevention
metastases
formulation method
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0851521A
Other languages
English (en)
Other versions
FR2928270A1 (fr
Inventor
Vanessa Bourgeaux
Yann Godfrin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Phaxiam Therapeutics SA
Original Assignee
Erytech Pharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR0851521A priority Critical patent/FR2928270B1/fr
Application filed by Erytech Pharma SA filed Critical Erytech Pharma SA
Priority to US12/921,962 priority patent/US20110014171A1/en
Priority to CN2009801083776A priority patent/CN101965182B/zh
Priority to JP2010550176A priority patent/JP6034001B2/ja
Priority to KR1020107019901A priority patent/KR101604451B1/ko
Priority to CA2718028A priority patent/CA2718028C/fr
Priority to PL09720545T priority patent/PL2249816T3/pl
Priority to ES09720545.4T priority patent/ES2544967T3/es
Priority to EP20090720545 priority patent/EP2249816B1/fr
Priority to AU2009224681A priority patent/AU2009224681B2/en
Priority to PCT/EP2009/052792 priority patent/WO2009112493A1/fr
Publication of FR2928270A1 publication Critical patent/FR2928270A1/fr
Priority to IL207713A priority patent/IL207713A/en
Application granted granted Critical
Publication of FR2928270B1 publication Critical patent/FR2928270B1/fr
Priority to HK11107026.0A priority patent/HK1152883A1/xx
Priority to US13/936,848 priority patent/US20140010795A1/en
Priority to US14/470,244 priority patent/US20140363413A1/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5063—Compounds of unknown constitution, e.g. material from plants or animals
    • A61K9/5068—Cell membranes or bacterial membranes enclosing drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Botany (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
FR0851521A 2008-03-10 2008-03-10 Formulation methode pour la prevention ou le traitement des metastases osseuses et autres maladies de l'os Expired - Fee Related FR2928270B1 (fr)

Priority Applications (15)

Application Number Priority Date Filing Date Title
FR0851521A FR2928270B1 (fr) 2008-03-10 2008-03-10 Formulation methode pour la prevention ou le traitement des metastases osseuses et autres maladies de l'os
PCT/EP2009/052792 WO2009112493A1 (fr) 2008-03-10 2009-03-10 Formulation et procédé pour la prévention et le traitement des métastase osseuses et d’autres maladies des os
JP2010550176A JP6034001B2 (ja) 2008-03-10 2009-03-10 骨転移または他の骨疾患の予防および治療のための配合物および方法
KR1020107019901A KR101604451B1 (ko) 2008-03-10 2009-03-10 골 전이 또는 기타 골 질환의 예방 및 치료를 위한 제제 및 방법
CA2718028A CA2718028C (fr) 2008-03-10 2009-03-10 Formulation d'erythrocytes encapsulant un diphosphonate pour la prevention et le traitement de metastases osseuses ou d'autres maladies des os
PL09720545T PL2249816T3 (pl) 2008-03-10 2009-03-10 Preparat i sposób zapobiegania i leczenia przerzutów do kości i innych chorób kości
ES09720545.4T ES2544967T3 (es) 2008-03-10 2009-03-10 Formulación y método para la prevención y el tratamiento de las metástasis óseas o de otras enfermedades óseas
EP20090720545 EP2249816B1 (fr) 2008-03-10 2009-03-10 Formulation et procédé pour la prévention et le traitement des métastase osseuses et d autres maladies des os
US12/921,962 US20110014171A1 (en) 2008-03-10 2009-03-10 Formulation and Method for the Prevention and Treatment of Bone Metastases or Other Bone Diseases
CN2009801083776A CN101965182B (zh) 2008-03-10 2009-03-10 用于预防和治疗骨转移或其它骨疾病的制剂和方法
AU2009224681A AU2009224681B2 (en) 2008-03-10 2009-03-10 Formulation and method for the prevention and treatment of bone metastases or other bone diseases
IL207713A IL207713A (en) 2008-03-10 2010-08-19 Erythrocytes wrapped in bisphosphonate wraps for use in prevention and treatment of bone metastases
HK11107026.0A HK1152883A1 (en) 2008-03-10 2011-07-07 Formulation and method for the prevention and treatment of bone metastases or other bone diseases
US13/936,848 US20140010795A1 (en) 2008-03-10 2013-07-08 Formulation and method for the prevention and treatment of bone metastases or other bone diseases
US14/470,244 US20140363413A1 (en) 2008-03-10 2014-08-27 Formulation and method for the prevention and treatment of bone metastases or other bone diseases

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0851521A FR2928270B1 (fr) 2008-03-10 2008-03-10 Formulation methode pour la prevention ou le traitement des metastases osseuses et autres maladies de l'os

Publications (2)

Publication Number Publication Date
FR2928270A1 FR2928270A1 (fr) 2009-09-11
FR2928270B1 true FR2928270B1 (fr) 2011-01-21

Family

ID=39865428

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0851521A Expired - Fee Related FR2928270B1 (fr) 2008-03-10 2008-03-10 Formulation methode pour la prevention ou le traitement des metastases osseuses et autres maladies de l'os

Country Status (13)

Country Link
US (3) US20110014171A1 (fr)
EP (1) EP2249816B1 (fr)
JP (1) JP6034001B2 (fr)
KR (1) KR101604451B1 (fr)
CN (1) CN101965182B (fr)
AU (1) AU2009224681B2 (fr)
CA (1) CA2718028C (fr)
ES (1) ES2544967T3 (fr)
FR (1) FR2928270B1 (fr)
HK (1) HK1152883A1 (fr)
IL (1) IL207713A (fr)
PL (1) PL2249816T3 (fr)
WO (1) WO2009112493A1 (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160016982A1 (en) 2009-07-31 2016-01-21 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
US9169279B2 (en) 2009-07-31 2015-10-27 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
ES2650665T3 (es) 2009-07-31 2018-01-19 Grünenthal GmbH Método de cristalización y biodisponibilidad
US9850296B2 (en) 2010-08-10 2017-12-26 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
US9517257B2 (en) 2010-08-10 2016-12-13 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
CA2807942C (fr) 2010-08-10 2021-07-27 Ecole Polytechnique Federale De Lausanne Agents therapeutiques se liant aux erythrocytes
WO2012071517A2 (fr) 2010-11-24 2012-05-31 Thar Pharmaceuticals, Inc. Nouvelles formes cristallines
FR3005420B1 (fr) * 2013-05-07 2015-09-18 Erytech Pharma Procede de stabilisation de suspensions d'erythrocytes encapsulant un principe actif, suspensions obtenues.
WO2015073587A2 (fr) 2013-11-18 2015-05-21 Rubius Therapeutics, Inc. Complexes membrane synthétique- récepteur
FR3017299B1 (fr) 2014-02-12 2018-05-18 Erytech Pharma Composition pharmaceutique comprenant des erythrocytes encapsulant une enzyme a plp et son cofacteur
US10046056B2 (en) 2014-02-21 2018-08-14 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
MX2016010835A (es) 2014-02-21 2017-07-11 Anokion Sa Terapeuticos dirigidos a la glucosa.
US10946079B2 (en) 2014-02-21 2021-03-16 Ecole Polytechnique Federale De Lausanne Glycotargeting therapeutics
US10953101B2 (en) 2014-02-21 2021-03-23 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
ES2865825T3 (es) 2014-04-01 2021-10-18 Rubius Therapeutics Inc Procedimientos y composiciones para inmunomodulación
JP2016025177A (ja) * 2014-07-18 2016-02-08 トヨタ自動車株式会社 スイッチング素子
HRP20220147T1 (hr) 2016-01-11 2022-04-15 Rubius Therapeutics, Inc. Pripravci i postupci povezani s multimodalnim terapijskim staničnim sustavima za indikacije raka
WO2017208070A1 (fr) 2016-05-31 2017-12-07 Grünenthal GmbH Acide bisphosphonique et coformeurs avec lysine, glycine, nicotinamide pour le traitement de la polyarthrite psoriasique
ES2867230T3 (es) * 2016-10-26 2021-10-20 Biointelligence Systems S L Composición bioactiva ósea y usos de la misma
EP3638296A1 (fr) 2017-06-16 2020-04-22 The University Of Chicago Compositions et procédés d'induction d'une tolérance immunitaire
CN110568114B (zh) * 2019-08-29 2021-12-28 福州佳宸生物科技有限公司 唑来膦酸和利塞膦酸的固相微萃取-高效液相色谱在线联用检测方法
WO2021228832A1 (fr) 2020-05-11 2021-11-18 Erytech Pharma Vésicules extracellulaires de globules rouges (vecgr) contenant des cargos et procédés d'utilisation et de production de celles-ci
CN112790155A (zh) * 2021-02-01 2021-05-14 华中科技大学同济医学院附属协和医院 一种验证sag预防环境异常相关性骨发育不良的方法
CN115400145B (zh) * 2021-05-26 2024-04-30 北京罗诺强施医药技术研发中心有限公司 治疗和预防骨质疏松症的方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2529463B1 (fr) * 1982-07-05 1986-01-10 Centre Nat Rech Scient Procede et dispositif pour l'encapsulation dans les erythrocytes d'au moins une substance a activite biologique, notamment des effecteurs allosteriques de l'hemoglobine et erythrocytes ainsi obtenus
FR2678512B1 (fr) * 1991-07-03 1995-06-30 Novacell Machine a internaliser.
EP0882448B1 (fr) * 1997-05-05 2005-01-12 DIDECO S.r.l. Méthode d'encapsulation d'agents biologiquement actifs dans des erythrocytes et appareil
CN1771972A (zh) * 2004-11-09 2006-05-17 胡才忠 氯屈膦酸脂质体及其制剂
US20070218116A1 (en) * 2006-03-14 2007-09-20 Schwendener Reto A Compositions and methods for the treatment of tumors and tumor metastases
WO2008016172A1 (fr) * 2006-08-04 2008-02-07 Kurume University Inhibiteur de métastase
CA2715379A1 (fr) * 2008-02-13 2009-08-20 Erytech Pharma Formulation et procede pour la prevention et le traitement de manifestation squelettique de la maladie de gaucher

Also Published As

Publication number Publication date
CN101965182A (zh) 2011-02-02
EP2249816B1 (fr) 2015-05-20
JP2011513464A (ja) 2011-04-28
ES2544967T3 (es) 2015-09-07
PL2249816T3 (pl) 2015-10-30
CA2718028C (fr) 2016-08-30
AU2009224681B2 (en) 2012-01-12
AU2009224681A1 (en) 2009-09-17
IL207713A0 (en) 2010-12-30
US20140010795A1 (en) 2014-01-09
FR2928270A1 (fr) 2009-09-11
JP6034001B2 (ja) 2016-11-30
WO2009112493A1 (fr) 2009-09-17
US20140363413A1 (en) 2014-12-11
CA2718028A1 (fr) 2009-09-17
US20110014171A1 (en) 2011-01-20
HK1152883A1 (en) 2012-03-16
KR20100129288A (ko) 2010-12-08
EP2249816A1 (fr) 2010-11-17
IL207713A (en) 2016-10-31
CN101965182B (zh) 2012-05-23
KR101604451B1 (ko) 2016-03-17

Similar Documents

Publication Publication Date Title
FR2928270B1 (fr) Formulation methode pour la prevention ou le traitement des metastases osseuses et autres maladies de l'os
MY173699A (en) Novel compounds for the treatment of diseases associated with amyloid of amyloid-like proteins
MA34169B1 (fr) Dérivés d'acide 1-amino-2-cyclopropyléthylboronique
PH12015500407A1 (en) Methods of treating hypertriglyceridemia
BR112012006283A2 (pt) formulação de adamts13 estabilizada, método para fabricar uma formulação de adamts13 estabilizada, kit, e métodos para tratar ou prevenir uma doença e para tratar ou previnir um enfarte
MD20150035A2 (ro) Inhibitori de tirozinkinaza Bruton
BR112012018386A2 (pt) "inibidores isoindolinona de fosfatidilinositol 3-quinase"
MY155961A (en) Chemical compounds 251
BR112014029245A2 (pt) métodos para diminuir a proteína convertase subtilisina/quexina tipo 9 (pcsk9)
MA33295B1 (fr) Nouvelle formulation de diclofénac
EA201290519A1 (ru) Положительные аллостерические модуляторы рецептора хинолин амида m1
MY161991A (en) Proteasome inhibitors
MY155649A (en) Pyridyloxyindoles inhibitors of vegf-r2 and use thereof for treatment of disease
BR112012027092A2 (pt) métodos e composiões para reduzir ou impedir a calcificação vascular durante a terapia de diálise peritoneal
BR112013020586A2 (pt) Uso de células derivadas de tecido do cordão umbilical
BR112014031394A2 (pt) composições e métodos para absorção transmucosa
EA200971107A1 (ru) Катехоламиновые производные, полезные для лечения болезни паркинсона
ATE538651T1 (de) Spiropiperidininhibitoren von beta-secretase zur behandlung von alzheimer-krankheit
MX2013012661A (es) Compuestos de piridazina biciclicos como inhibidores pim.
EA201390826A1 (ru) ПИРИМИДИНОНОВЫЕ СОЕДИНЕНИЯ ДЛЯ ПРИМЕНЕНИЯ В ЛЕЧЕНИИ ЗАБОЛЕВАНИЙ ИЛИ СОСТОЯНИЙ, ОПОСРЕДОВАННЫХ Lp-PLA
CY1115725T1 (el) Ενωσεις, συνθεσεις και μεθοδοι για την θεραπευτικη αγωγη των βητα-αμυλοειδικων ασθενειων και συνουκλεϊνοπαθειων
WO2012138913A3 (fr) Plateforme d'hyperthermie immuno-magnétique in vivo pour toute cellule ou tout virus ayant un récepteur de surface cible
BR112013005673A2 (pt) uso de lipase de ácido lisossomal para tratamento de deficiência de lipase de ácido lisossomal em pacientes
MA35895B1 (fr) Inhibiteurs d'iap
ATE555116T1 (de) Ahcy-hydrolasehemmer zur behandlung von hyperhomocysteinämie

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 9

ST Notification of lapse

Effective date: 20171130